Prognostic and therapeutic relevance of molecular subtypes in high-grade serous ovarian cancer

Journal of the National Cancer Institute

Volumn 106, Issue 10, 2014, Pages

  Konecny, Gottfried E ^a   Wang, Chen ^b   Hamidi, Habib ^a   Winterhoff, Boris ^b   Kalli, Kimberly R ^b   Dering, Judy ^a   Ginther, Charles ^a   Chen, Hsiao Wang ^a   Dowdy, Sean ^b   Cliby, William ^b   Gostout, Bobbie ^b   Podratz, Karl C ^b   Keeney, Gary ^b   Wang, He Jing ^a   Hartmann, Lynn C ^b   Slamon, Dennis J ^a   Goode, Ellen L ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INTERFERON REGULATORY FACTOR 7; PROGRAMMED DEATH 1 LIGAND 1; TRANSCRIPTOME; TUMOR MARKER;

ARTICLE; CANCER CLASSIFICATION; CANCER GRADING; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; CYTOREDUCTIVE SURGERY; FEMALE; GENE EXPRESSION PROFILING; GROUPS BY AGE; HIGH GRADE SEROUS OVARIAN CANCER; HUMAN; HUMORAL IMMUNITY; IMMUNE EVASION; IMMUNOREACTIVITY; MAJOR CLINICAL STUDY; MESENCHYME; OVARY CANCER; OVERALL SURVIVAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); STATISTICAL SIGNIFICANCE; TUMOR DIFFERENTIATION; TUMOR GROWTH; ADULT; AGED; CHEMISTRY; CYSTADENOCARCINOMA; GENE EXPRESSION REGULATION; KAPLAN MEIER METHOD; MIDDLE AGED; MORTALITY; OVARY TUMOR; PATHOLOGY; PREDICTIVE VALUE; PROGNOSIS; RETROSPECTIVE STUDY; RISK; SAMPLE SIZE; TISSUE MICROARRAY;

ADULT; AGED; CYSTADENOCARCINOMA, SEROUS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; KAPLAN-MEIER ESTIMATE; MIDDLE AGED; NEOPLASM GRADING; ODDS RATIO; OVARIAN NEOPLASMS; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RETROSPECTIVE STUDIES; SAMPLE SIZE; TISSUE ARRAY ANALYSIS; TRANSCRIPTOME; TUMOR MARKERS, BIOLOGICAL;

EID: 84985034791     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/dju249     Document Type: Article

References (15)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin. 2013;63(1):11-30.
2. Yap TA, Carden CP, Kaye SB. Beyond chemotherapy: targeted therapies in ovarian cancer. Nat Rev Cancer. 2009;9(3):167-181.
3. Tothill RW, Tinker AV, George J, et al. Novel molecular subtypes of serous and endometrioid ovarian cancer linked to clinical outcome. Clin Cancer Res. 2008;14(16):5198-5208.
4. Cancer Genome Atlas Research Network. Integrated genomic analyses of ovarian carcinoma. Nature. 2011;474(7353):609-615.
5. Cannistra SA. Cancer of the ovary. N Engl J Med. 2004;351(24):2519-2529.
6. Verhaak RG, Tamayo P, Yang JY, et al. Prognostically relevant gene signatures of high-grade serous ovarian carcinoma. J Clin Invest. 2013;123(1):517-525.
7. van de Vijver MJ, He YD, van't Veer LJ, et al. A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med. 2002;347(25):1999-2009.
8. Bonome T, Levine DA, Shih J, et al. A gene signature predicting for survival in suboptimally debulked patients with ovarian cancer. Cancer Res. 2008;68(13):5478-5486.
9. Tibshirani R, Hastie T, Narasimhan B, Chu G. Diagnosis of multiple cancer types by shrunken centroids of gene expression. Proc Natl Acad Sci U S A. 2002;99(10):6567-6572.
10. Piya S, Moon AR, Song PI, et al. Suppression of IRF4 by IRF1, 3, and 7 in Noxa expression is a necessary event for IFN-?-mediated tumor elimination. Mol Cancer Res. 2011;9(10):1356-1365.
11. Ribas A. Tumor immunotherapy directed at PD-1. N Engl J Med. 2012;366(26):2517-2519.
12. Topalian SL, Hodi FS, Brahmer JR, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med. 2012;366(26):2443-2454.
13. Hamid O, Robert C, Daud A, et al. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N Engl J Med. 2013;369(2):134-144.
14. April C, Klotzle B, Royce T, et al. Wholegenome gene expression profiling of formalinfixed, paraffin-embedded tissue samples. PLoS One. 2009;4(12):e8162.
15. Geiss GK, Bumgarner RE, Birditt B, et al. Direct multiplexed measurement of gene expression with color-coded probe pairs. Nat Biotechnol. 2008;26(3):317-325.